[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

January 2017 - April 2015

Decade

Year

Issue

May 1, 2015, Vol 1, No. 2, Pages 125-260

In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):125. doi:10.1001/jamaoncol.2015.0723
Viewpoint

The Cost and Value of Anti–Epidermal Growth Factor Receptor TherapiesLet's Not Be Rash

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):141-142. doi:10.1001/jamaoncol.2015.0287

This Viewpoint advocates avoiding the use of first-line cetuximab- or panitumumab-containing regimens for patients with RAS wild-type colorectal cancer.

Imatinib—A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):143-144. doi:10.1001/jamaoncol.2015.50

This Viewpoint states that imatinib’s safety and effectiveness compare favorably with those of newer drugs used to treat chronic myeloid leukemia and points out that the expiration of imatinib’s patent confers a substantial cost advantage.

Hypofractionated Whole Breast RadiotherapyAdapting to the Evidence

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):144-145. doi:10.1001/jamaoncol.2014.264

This Viewpoint discusses the slow adoption by the radiation oncology community of hypofractionated whole-breast radiation therapy.

Editorial

EGFR Mutations in Non–Small-Cell Lung CancerFind, Divide, and Conquer

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):146-148. doi:10.1001/jamaoncol.2014.278
Original Investigation

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):149-157. doi:10.1001/jamaoncol.2014.257

This study reporting a secondary objective of the EURTAC trial found that a sensitive assay can be used to assess epidermal growth factor receptor mutations in circulating free DNA in advanced non-small-cell lung cancer and that the L858R mutation in cfDNA may be a novel surrogate prognostic marker.

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):158-166. doi:10.1001/jamaoncol.2015.43

The 21-gene recurrence score assay was adopted quickly in clinical practice after Medicare coverage approval in 2006 and utilization seems equitable and consistent with guidelines across geographic and racial groups.

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):168-174. doi:10.1001/jamaoncol.2015.23

The authors estimate the impact of prior knowledge of MGUS (monoclonal gammopathy of undetermined significance) diagnosis and comorbidities on multiple myeloma (MM) survival. Patients with MM with prior knowledge of MGUS had better MM survival. The observation that a low M-protein concentration at MGUS diagnosis was associated with poorer MM survival may reflect less frequent clinical follow-up. Their observations stress the importance of clinical follow-up in MGUS, regardless of risk stratification.

Patient Perception of Physician Compassion After a More Optimistic vs a Less Optimistic MessageA Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):176-183. doi:10.1001/jamaoncol.2014.297

This randomized clinical trial found that patients perceived a higher level of compassion and preferred physicians who provided a more optimistic message.

Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast CancersPotential Implications for the Choosing Wisely Campaign

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):185-194. doi:10.1001/jamaoncol.2015.37

There is an association by hospital referral region between inappropriate prostate and breast cancer imaging rates.

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):196-202. doi:10.1001/jamaoncol.2015.0203

This probabilistic decision model study found that the value of providing access to new treatments on the basis of surrogate end points, and progression-free survival in non–small-cell lung cancer in particular, likely varies considerably.

Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell CarcinomaA Prospective Cohort Study

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):204-212. doi:10.1001/jamaoncol.2015.0213

Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry

Abstract Full Text
free access has active quiz
JAMA Oncol. 2015;1(2):214-221. doi:10.1001/jamaoncol.2015.0197

A multicenter cross-sectional cohort study was conducted of individuals recruited to the Colon Cancer Family Registry from 1998 through 2007. In this large cohort of patients with early-onset colorectal cancer, germline TP53 mutations were detected at a frequency comparable with the published prevalence of germline APC mutations in colorectal cancer.

Racial/Ethnic Differences in Patients’ Selection of Surgeons and Hospitals for Breast Cancer Surgery

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):222-230. doi:10.1001/jamaoncol.2015.20

In a survey study to examine racial/ethnic differences in how women selected surgeons/hospitals for breast cancer surgery, the authors found that minority patients were less actively involved in these selections, relying more on physician referral and health plans.

Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in MenThe Cooper Center Longitudinal Study

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):231-237. doi:10.1001/jamaoncol.2015.0226

This study found an inverse association between midlife cardiorespiratory fitness (CRF) and incident lung and colorectal cancer but not prostate cancer. High midlife CRF is associated with lower risk of cause-specific mortality in those diagnosed as having cancer at Medicare age.

Brief Report

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):238-244. doi:10.1001/jamaoncol.2015.34

This gene-sequencing case report found that selective erlotinib use in head and neck squamous cell carcinoma may be informed by precision oncology approaches.

Invited Commentary

Refining Treatment Decisions in Older Patients With Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):166-167. doi:10.1001/jamaoncol.2015.32

Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):174-175. doi:10.1001/jamaoncol.2015.33

The Complexities of Compassion in Patient Care

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):183-184. doi:10.1001/jamaoncol.2014.296

Diagnostic Imaging Use for Patients With CancerOpportunities to Enhance Value

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):194-195. doi:10.1001/jamaoncol.2015.31

Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):202-203. doi:10.1001/jamaoncol.2015.0407

Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):212-213. doi:10.1001/jamaoncol.2015.0262
From The JAMA Network

The Use of Hypofractionated Whole Breast Irradiation in Treatment of Patients With Early-Stage Breast Cancer in the United States

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):245-246. doi:10.1001/jamaoncol.2014.321
JAMA Oncology Clinical Challenge

Atypical Imaging Findings in an Immunocompetent Patient

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):247-248. doi:10.1001/jamaoncol.2015.0298
Research Letter

Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell TransplantationA Pilot Therapeutic Study

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):249-252. doi:10.1001/jamaoncol.2014.316

This case series describes outcomes for patients given low-dose decitabine for treatment of isolated thrombocytopenia following allogeneic hematopoietic stem cell transplantation.

Suggestibility of Oncologists’ Clinical Estimates

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):251-253. doi:10.1001/jamaoncol.2015.62
Observation

Alpha Emitter Radium 223 in High-Risk OsteosarcomaFirst Clinical Evidence of Response and Blood-Brain Barrier Penetration

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):253-255. doi:10.1001/jamaoncol.2014.289
Correction

Incorrect Drug Name

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):255. doi:10.1001/jamaoncol.2015.1156
JAMA Oncology Patient Page

Malignant Pleural Effusions

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):260. doi:10.1001/jamaoncol.2015.0671
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(2):132. doi:10.1001/jamaoncol.2014.244
×